...
首页> 外文期刊>International immunopharmacology >Th17 and regulatory T cell subsets in diseases and clinical application.
【24h】

Th17 and regulatory T cell subsets in diseases and clinical application.

机译:Th17和调节性T细胞亚群在疾病和临床中的应用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the past decade it has been established that regulatory T cells (Tregs) control all immune responses. As the induction and effector mechanisms used by Tregs are being unraveled, it is emerging that a reciprocal population of CD4(+) T lymphocytes exists in the immune system that produces inflammatory cytokine IL-17, and coined "Th17 cells". Th17 cells have been implicated in the pathogenesis of many forms of human disease. The development, function, mechanism of action, and homeostasis of Tregs and Th17 cells, and the reciprocal control between Tregs and Th17 cells were presented at the Second International Conference on Regulatory T Cells and Th17 Cells and Clinical Application in Human Diseases in Shanghai on 17-20 July 2010 (China Tregs/Th17 2010). In this Special Issue of International Immunopharmacology, several paper submitted to the conference will highlight the biology of Tregs and Th17 cells, and their clinical application in human disease.
机译:在过去的十年中,已经确定调节性T细胞(Tregs)控制所有免疫反应。随着Tregs所使用的诱导和效应机制的阐明,正在出现一种相互的CD4(+)T淋巴细胞群体,其免疫系统中会产生炎症性细胞因子IL-17,并产生了“ Th17细胞”。 Th17细胞与多种形式的人类疾病的发病机制有关。 Tregs和Th17细胞的发育,功能,作用机制和体内稳态以及Tregs和Th17细胞之间的相互控制在17日于上海举行的第二届国际调节性T细胞和Th17细胞及其在人类疾病中的临床应用国际会议上进行了介绍。 2010年7月20日至20日(China Tregs / Th17 2010)。在本期《国际免疫药理学专刊》中,提交给会议的几篇论文将重点介绍Tregs和Th17细胞的生物学及其在人类疾病中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号